Myriad Genetics Shares Fall, Company Reports Earnings and CEO Change

Dow Jones

25 Feb

By Josh Beckerman

Myriad Genetics shares were down 6.5% to $12.88 after hours as the company reported earnings and said Chief Executive Paul J. Diaz will leave the company April 30.

The genetic testing and precision medicine company said Monday fourth-quarter revenue rose 7% to $210.6 million. Adjusted net income declined to $3.2 million from $3.5 million. Myriad reaffirmed 2025 guidance.

Myriad said Chief Operating Officer Sam Raha will become CEO. Mark S. Verratti, Myriad's chief commercial officer, will be COO. Diaz, who joined Myriad in 2020, is returning to private equity firm Cressey & Co.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

February 24, 2025 17:49 ET (22:49 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2514570781"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2514570781\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2514570781?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-25 06:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2514570781","market":"fut","top_or_hot":-1,"title":"Myriad Genetics Shares Fall, Company Reports Earnings and CEO Change","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre>\n \n</pre>\n<p>\n  Myriad Genetics shares were down 6.5% to $12.88 after hours as the company reported earnings and said Chief Executive Paul J. Diaz will leave the company April 30. \n</p>\n<p>\n  The genetic testing and precision medicine company said Monday fourth-quarter revenue rose 7% to $210.6 million. Adjusted net income declined to $3.2 million from $3.5 million. Myriad reaffirmed 2025 guidance. \n</p>\n<p>\n  Myriad said Chief Operating Officer Sam Raha will become CEO. Mark S. Verratti, Myriad's chief commercial officer, will be COO. Diaz, who joined Myriad in 2020, is returning to private equity firm Cressey &amp; Co. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 24, 2025 17:49 ET (22:49 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Myriad Genetics Shares Fall, Company Reports Earnings and CEO Change</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMyriad Genetics Shares Fall, Company Reports Earnings and CEO Change\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-02-25 06:49</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre>\n \n</pre>\n<p>\n  Myriad Genetics shares were down 6.5% to $12.88 after hours as the company reported earnings and said Chief Executive Paul J. Diaz will leave the company April 30. \n</p>\n<p>\n  The genetic testing and precision medicine company said Monday fourth-quarter revenue rose 7% to $210.6 million. Adjusted net income declined to $3.2 million from $3.5 million. Myriad reaffirmed 2025 guidance. \n</p>\n<p>\n  Myriad said Chief Operating Officer Sam Raha will become CEO. Mark S. Verratti, Myriad's chief commercial officer, will be COO. Diaz, who joined Myriad in 2020, is returning to private equity firm Cressey &amp; Co. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 24, 2025 17:49 ET (22:49 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MYGN","symbol_name":"万基遗传","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2514570781","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2514570781","pubTimestamp":1740437340,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Myriad Genetics shares were down 6.5% to $12.88 after hours as the company reported earnings and said Chief Executive Paul J. Diaz will leave the company April 30.The genetic testing and precision medicine company said Monday fourth-quarter revenue rose 7% to $210.6 million. Adjusted net income declined to $3.2 million from $3.5 million. Myriad reaffirmed 2025 guidance.Myriad said Chief Operating Officer Sam Raha will become CEO. Mark S. Verratti, Myriad's chief commercial officer, will be COO. Diaz, who joined Myriad in 2020, is returning to private equity firm Cressey & Co.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"MYGN":"万基遗传"},"translate_title":"Myriad Genetics股价下跌，公司报告收益和首席执行官变动","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MYGN":1},"content_text":"By Josh Beckerman \n\n\n \n\n\n  Myriad Genetics shares were down 6.5% to $12.88 after hours as the company reported earnings and said Chief Executive Paul J. Diaz will leave the company April 30. \n\n\n  The genetic testing and precision medicine company said Monday fourth-quarter revenue rose 7% to $210.6 million. Adjusted net income declined to $3.2 million from $3.5 million. Myriad reaffirmed 2025 guidance. \n\n\n  Myriad said Chief Operating Officer Sam Raha will become CEO. Mark S. Verratti, Myriad's chief commercial officer, will be COO. Diaz, who joined Myriad in 2020, is returning to private equity firm Cressey & Co. \n\n\n \n\n\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 24, 2025 17:49 ET (22:49 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":1}}}